

Volumetric Image Analysis Promotes Accurate Assessment of Patient Response to Cancer Treatment

Date: 03-10-2010 11:10 AM CET

Category: [Health & Medicine](#)

Press release from: [Definiens AG](#)

Agency: **Ricochet Public Relations, Inc.**

Definiens Launches Definiens LymphExpert™ Version 2.0 in Europe

Munich, Germany and Parsippany, New Jersey – March 5, 2010 – Definiens, the number one Enterprise Image Intelligence® company, today announced the launch of Definiens LymphExpert™ Version 2.0 in the European market, following CE-mark approval. Definiens LymphExpert is a software application that assists radiology professionals in the identification, analysis and evaluation of lymph nodes in CT images over time.

Lymph nodes play a critical role in the assessment of cancer progression and the staging of therapy control. The earlier the metastatic spread of cancer can be detected, the higher the chances are for successful treatment. Currently, RECIST 1.1 is the most established standard for evaluating patient responses to treatment. Under RECIST, the diameter of a tumor is measured to provide a two-dimensional representation. However, tumors do not always expand or contract uniformly and changes in diameter do not necessarily provide a complete picture of tumor growth.

Definiens LymphExpert automatically segments lymph nodes and analyzes their properties according to RECIST and WHO criteria. In addition, Definiens LymphExpert is able to reliably quantify the volume of lymph nodes and their volumetric changes over time, providing a more complete picture of node size and growth. Accurate and detailed analysis of node volume may allow radiologists to detect metastasizing cancer earlier and more readily evaluate the efficacy of treatment protocols. Definiens LymphExpert promotes the development of personalized treatments, reducing costs and avoiding unnecessary procedures for better patient outcomes.

“It is becoming increasingly clear that one- and two-dimensional RECIST and WHO criteria provide only partial information about tumor progression,” said Frank-P. Klein, Vice President, Medical Imaging at Definiens. “Quantifying the volume of tumors or lymph nodes can potentially provide a much more accurate determination of changes in size and other dimensions.”

Definiens LymphExpert Version 2.0 provides accurate and reproducible results. It reduces inter- and intra-reader variability in the assessment of CT images, enabling clinicians to work more efficiently. The software allows users to conduct side-by-side comparisons of images taken at different stages of lymph node development, accurately tracking a cancer’s progression or remission. Data can be imported from a wide variety of imaging acquisition devices, making it applicable to radiologists working in hospitals, cancer centers, CROs, pharmaceutical companies, teleradiology service providers and academic institutions. Additionally, Definiens LymphExpert 2.0 incorporates a thin client architecture that gives radiologists remote access to their image data and analysis tools from any workstation at any time. Image analysis results can thereby be obtained faster and at a lower cost.

Definiens is demonstrating Definiens LymphExpert Version 2.0 at the European Congress of Radiology in Vienna, March 4 – 8 at the company’s booth [First Level Gallery, booth number 606]. More information on Definiens LymphExpert is available at www.definiens.com/lymphexpert.

Definiens in Medical Imaging

By automating image analysis, Definiens supports healthcare providers in analyzing and interpreting vast numbers of digital images accurately and consistently. Definiens improves the analysis of tissue samples and non-invasive imaging, enabling translational medicine - from early diagnosis to personalized treatment.

About Definiens

Definiens is the number one Enterprise Image Intelligence® company for analyzing and interpreting images on every scale,

from microscopic cell structures to satellite images. The Definiens Cognition Network Technology[®], developed by Nobel Laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Medical, Life Science and Earth Science markets. The technology is modeled on the powerful human cognitive perception processes to extract intelligence from images. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better business decisions. The company is headquartered in Munich, Germany and has offices in the United States. Further information is available at www.definiens.com.

Definiens, Definiens Cellenger, Definiens Cognition Network Technology, Definiens eCognition, Definiens LymphExpert, Enterprise Image Intelligence, Definiens TissueStudio and Understanding Images are trademarks or registered trademarks of Definiens.

Press Contacts

Ricochet Public Relations

Garry Clark

Phone: +1 (212) 679-3300 114

gclark@ricochetpr.com

Definiens

Eva Tietz

Manager Corporate Communications

etietz@definiens.com

Definiens is the No. 1 Enterprise Image Intelligence[®] company. We support customers in analyzing and interpreting images on every scale, from microscopic cell structures to satellite images.

Our patented Definiens Cognition Network Technology[®] has been developed by Nobel Laureate, Prof. Dr. Gerd Binnig and his team. It emulates the powerful human cognitive processes that extract intelligence from images.

At all powers of magnification, our technology enables customers to accomplish every task of image analysis, delivering deeper insights, faster results and better decisions.

Definiens AG

Eva Tietz

Manager Corporate Communications

Trappentreustrasse 1

80339 München

Germany

Tel. +49-89-23 11 80-0

etietz@definiens.com

[You can find this press release here](#)